Drug Trial Radar · NCT06999083
A Study to Evaluate Single-dose of HB0043 in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Jun 3, 2025
Primary completion
Feb 12, 2026
Study completion Apr 30, 2026
Sponsor
- Lead sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 31, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of this study is to investigate the safety and tolerability of HB0043 in healthy subjects following single-dose.
Conditions
- Healthy
Interventions
HB0043Drug
HB0043 Drug Product
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects with drug related adverse events (AEs)Time frame: Up to 1200 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
New Zealand Clinical Research , Grafton, Auckland, 3 Ferncroft Street,
Auckland, Grafton, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.